TDT

LBank Exchange Will List 300FIT Network (FIT) on March 26, 2024

Retrieved on: 
Monday, March 25, 2024
Athlete, Web3, Intellectual property, Non-fungible token, FIT, TDT, Sport, NFT, Ecosystem

LBank Exchange is thrilled to announce the upcoming listing of 300FIT Network (FIT), representing a pioneering shift in the sports industry, leveraging the potential of Web3.0 technologies to forge a unique ecosystem centered around sports NFTs and digital assets.

Key Points: 
  • LBank Exchange is thrilled to announce the upcoming listing of 300FIT Network (FIT), representing a pioneering shift in the sports industry, leveraging the potential of Web3.0 technologies to forge a unique ecosystem centered around sports NFTs and digital assets.
  • By doing so, 300FIT addresses the industry's long-standing challenges of underutilization and inadequate compensation for athletes' contributions, offering a new revenue model that benefits both athletes and fans.
  • At the core of the 300FIT Network is the TDT ecosystem, which facilitates direct interaction and transaction between athletes, fans, and brands.
  • 300FIT Network is not just about enhancing the sports industry's economic model; it's about revolutionizing fan engagement and opening new avenues for athlete support and interaction.

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Adolescence, Research, Biotechnology, Gene editing, ASH, FDA, Food, File, TDT, BLA, BCL11A, Safety, Society, Collaboration, Vertex Pharmaceuticals, Patent, Editas Medicine, Patient, Cas9, Sickle cell disease, Public expenditure, Poster, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.
  • In 2023, Editas Medicine strengthened and focused its discovery organization to build an in vivo gene editing pipeline.
  • Editas Medicine plans to participate in the following investor events:
    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m.
  • ET to provide and discuss a corporate update and financial results for the fourth quarter and full year of 2023.

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Sale, CD19, Lupus, RNA, EAP, LNP, Liver, Cardiovascular disease, CRISPR Therapeutics, CRSP, Therapy, Vertex Pharmaceuticals, Sickle cell disease, Autoimmunity, T1D, G&A, Bill, Partnership, Pharmacology, Guide, SCD, TDT, Pharmacokinetics, Clinical trial, ANGPTL3, United, Hypertriglyceridemia, Medicaid, Research, Human, CRISPR, Gene editing, CD70, Stem cell, ADC, Risk, Genetics, Patient, SLE, KSA, Moyamoya disease, Pharmaceutical industry

R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.

Key Points: 
  • R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses were $16.5 million for the fourth quarter of 2023, compared to $21.2 million for the fourth quarter of 2022.
  • Collaboration Expense: Collaboration expense, net, was $20.0 million for the fourth quarter of 2023, compared to $6.8 million for the fourth quarter of 2022.
  • Net Income (Loss): Net income was $89.3 million for the fourth quarter of 2023, compared to a net loss of $110.6 million for the fourth quarter of 2022.

Unibet and Tour de Tietema launches heart health awareness campaign - 'Follow Your Heart'

Retrieved on: 
Wednesday, February 14, 2024
Resuscitation, TDT, Kindred, Follow Your Heart, Sport, Human, Kindred Group, Survival, Heart, Augmented reality, DNA

VALLETTA, Malta, Feb. 14, 2024 /PRNewswire/ -- Unibet in Belgium and the Netherlands launches a campaign with the Dutch cycling team Tour de Tietema to raise awareness and educate the public about heart health issues within the cycling community.

Key Points: 
  • VALLETTA, Malta, Feb. 14, 2024 /PRNewswire/ -- Unibet in Belgium and the Netherlands launches a campaign with the Dutch cycling team Tour de Tietema to raise awareness and educate the public about heart health issues within the cycling community.
  • The campaign is called 'Follow Your Heart'.
  • Kindred Group plc's (Kindred) flagship brand Unibet has, together with Tour de Tietema (TDT), developed an online learning tool in response to the growing concern over heart health issues within the cycling community.
  • In addition, the cycling team will wear a custom exclusive jersey to draw attention to the importance of heart health.

Unibet and Tour de Tietema launches heart health awareness campaign - 'Follow Your Heart'

Retrieved on: 
Wednesday, February 14, 2024
Resuscitation, TDT, Kindred, Follow Your Heart, Sport, Human, Kindred Group, Survival, Heart, Augmented reality, DNA

VALLETTA, Malta, Feb. 14, 2024 /PRNewswire/ -- Unibet in Belgium and the Netherlands launches a campaign with the Dutch cycling team Tour de Tietema to raise awareness and educate the public about heart health issues within the cycling community.

Key Points: 
  • VALLETTA, Malta, Feb. 14, 2024 /PRNewswire/ -- Unibet in Belgium and the Netherlands launches a campaign with the Dutch cycling team Tour de Tietema to raise awareness and educate the public about heart health issues within the cycling community.
  • The campaign is called 'Follow Your Heart'.
  • Kindred Group plc's (Kindred) flagship brand Unibet has, together with Tour de Tietema (TDT), developed an online learning tool in response to the growing concern over heart health issues within the cycling community.
  • In addition, the cycling team will wear a custom exclusive jersey to draw attention to the importance of heart health.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Retrieved on: 
Tuesday, February 13, 2024
Hospital, European Commission, CRISPR, Volatile organic compound, Gene, HSC, TDT, SCD, Vertex, CRISPR Therapeutics, European, CRSP, Civil service commission, Haematopoietic system, Therapy, Patient, Sickle cell disease

ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available.

Key Points: 
  • “The approval by the European Commission is yet another important regulatory milestone underscoring the potentially transformative benefit of CASGEVY for patients with severe sickle cell disease and transfusion-dependent beta thalassemia,” said Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics.
  • Vertex is working closely with national health authorities in the European Union (EU) to secure access for eligible patients as quickly as possible.
  • Through this work, they have secured early access for eligible TDT patients in France ahead of the national reimbursement process.
  • There are currently three activated ATCs in the EU with plans to activate a total of approximately 25 centers across Europe.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Retrieved on: 
Tuesday, February 13, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hospital, European Commission, CRISPR, Volatile organic compound, Hematology, Gene, HSC, VRTX, TDT, SCD, European, Civil service commission, Haematopoietic system, Patient, Sickle cell disease, Bambino, Catholic higher education, Pediatrics, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.
  • CASGEVY is the only genetic therapy approved for SCD and TDT patients in the European Union (EU) and with this approval, there are now more than 8,000 patients potentially eligible for treatment.
  • Through this work, Vertex has secured early access for eligible TDT patients in France ahead of the national reimbursement process.
  • Vertex continues to engage with hospitals experienced in stem cell transplantation to establish a network of independently operated authorized treatment centers (ATCs) for the administration of CASGEVY.

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

Retrieved on: 
Tuesday, January 23, 2024
SCD, CMC, Patient, European Medicines Agency, Collaboration, Chemistry, CRISPR, GMP, EMA, Sickle cell disease, TDT, FDA, Food and Drug Administration, Committee, Vertex Pharmaceuticals, Pharmaceutical industry

KAISERAUGST, Switzerland, Jan. 23, 2024 /PRNewswire/ -- Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises.

Key Points: 
  • KAISERAUGST, Switzerland, Jan. 23, 2024 /PRNewswire/ -- Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy.
  • The companies' collaboration included establishing the testing methods that will be scaled for commercializing CASGEVY.
  • Solvias also has invested significantly in preparing one of its global facilities to support the commercial release work for this transformative therapy.
  • "Solvias is honored to be playing a critical role in delivering this breakthrough therapy to patients.

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

Retrieved on: 
Tuesday, January 23, 2024
SCD, CMC, Patient, European Medicines Agency, Collaboration, Chemistry, CRISPR, GMP, EMA, Sickle cell disease, TDT, FDA, Food and Drug Administration, Committee, Vertex Pharmaceuticals, Pharmaceutical industry

KAISERAUGST, Switzerland, Jan. 23, 2024 /PRNewswire/ -- Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises.

Key Points: 
  • KAISERAUGST, Switzerland, Jan. 23, 2024 /PRNewswire/ -- Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy.
  • The companies' collaboration included establishing the testing methods that will be scaled for commercializing CASGEVY.
  • Solvias also has invested significantly in preparing one of its global facilities to support the commercial release work for this transformative therapy.
  • "Solvias is honored to be playing a critical role in delivering this breakthrough therapy to patients.

Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics

Retrieved on: 
Wednesday, January 17, 2024
Vertex Pharmaceuticals, Patient, Biologics license application, Therapy, Endocrine system, TGF, Heart, LAS, HBA, Spleen, Diagnosis, Anemia, Mouse, Thalassemia, Beta thalassemia, HB, CBC, RBC, Pharmacosmos, Disease, Iron overload, TDT, EU4, FDA, Blas, Prevalence, Liver, Novo Nordisk, PDUFA, Red blood cell, CRISPR Therapeutics, Hemoglobin A, Cell, Iron, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Beta-thalassemia Market Insights report includes a comprehensive understanding of current treatment practices, beta-thalassemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • According to DelveInsight's analysis, the market size for beta-thalassemia across the 7MM is expected to grow with a significant CAGR by 2032.
  • The promising beta-thalassemia therapies in the pipeline include CTX001, EDIT-301, Mitapivat, ACE-536, Panobinostat, Etavopivat tablets, and others.
  • In September 2023, Pharmacosmos has initiated a Phase II trial of SP-420 in patients with transfusion-dependent β-thalassemia.
  • In June 2023, FDA accepted the Biologics License Application (BLAs) of exagamglogene autotemcel (exa-cel) for transfusion-dependent beta thalassemia (TDT).